2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
563
Neoplasms
462
Carcinoma, Non-Small-Cell Lung
422
Prostatic Neoplasms
344
Colorectal Neoplasms
325
Lung Neoplasms
269
Multiple Myeloma
235
Neoplasm Metastasis
197
Pancreatic Neoplasms
189
Leukemia, Myeloid, Acute
187
Ovarian Neoplasms
182
Melanoma
153
Squamous Cell Carcinoma of Head and Neck
143
Head and Neck Neoplasms
121
Recurrence
119
Carcinoma, Renal Cell
119
Carcinoma, Hepatocellular
119
Stomach Neoplasms
116
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Glioblastoma
114
Endometrial Neoplasms
114
Lymphoma
113
Brain Neoplasms
111
Lymphoma, Non-Hodgkin
108
Uterine Cervical Neoplasms
101
Triple Negative Breast Neoplasms
99
Hematologic Neoplasms
98
Urinary Bladder Neoplasms
97
Glioma
91
Leukemia, Lymphocytic, Chronic, B-Cell
88
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Amyloid Neuropathies, Familial
×
30 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled